Vinay Prasad, the U.S. Food and Drug Administration's top vaccine regulator, is returning to his post less than two weeks ...

Abbott and Boston Scientific are among the investors in SetPoint, whose neurostimulation device gained FDA approval last ...

Shortly after obtaining a green light from the FDA, SetPoint Medical announced $140 million in new funding to juice the commercialization of its neuromodulation implant for rheumatoid art | Shortly ...

Our fair value estimate for Olympus is JPY 2,390 per share. It implies a terminal enterprise value/EBITDA multiple of 12.8 times, roughly in line with its Japanese peers but lower than leading US ...

While neither warning is classified as a recall, the FDA has provided additional information for the two products. Boston ...

The update covers devices used in procedures to implant the company’s Watchman heart device.

The FDA is reviewing Boston Scientific's defibrillator leads after reports of rising shock impedance and 16 related deaths.

The FDA has issued an early communication to warn of updated instructions for use for certain Boston Scientific Watchman access systems.

The U.S. FDA posted an Aug. 6 early alert regarding the use of the Watchman left atrial appendage device by Boston Scientific Corp., citing instances in which the device’s delivery system is ...

The FDA has issued an alert about a potentially high-risk issue involving models of Boston Scientific’s Watchman Access Systems, which are used to provide vascular and transseptal access during ...

Boston Scientific Corporation (NYSE:BSX) is one of the most profitable growth stocks to buy according to billionaires. On July 24, Oppenheimer raised its price target for Boston Scientific from $110 ...

Key Takeaways Two Boston Scientific heart devices have been linked to serious injuries and deathsOne device may fail to ...